PROCEPT BioRobotics financials
$18.22+5.62%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $308.1M | $224.5M | $136.2M | $75.0M | $34.5M |
| Gross profit | $196.2M | $137.1M | $71.0M | $37.1M | $15.9M |
| Gross margin | 63.7% | 61.1% | 52.2% | 49.4% | 46.0% |
| Operating income | -$103.9M | -$96.6M | -$109.2M | -$80.7M | -$54.2M |
| Net income | -$95.6M | -$91.4M | -$105.9M | -$87.2M | -$59.9M |
| Net margin | −31.0% | −40.7% | −77.8% | −116.2% | −173.6% |
| Diluted EPS | $-1.72 | $-1.75 | $-2.24 | $-1.96 | $-3.63 |
| EBITDA | -$97.5M | -$91.4M | -$105.4M | -$77.9M | -$50.8M |
| Operating cash flow | -$49.0M | -$99.2M | -$108.0M | -$80.4M | -$57.3M |
| Free cash flow | -$58.3M | -$103.6M | -$133.2M | -$83.0M | -$57.9M |
| Diluted shares | 55.5M | 52.1M | 47.3M | 44.4M | 16.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $286.5M | $333.7M | $257.2M | $221.9M | $304.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $51.6M | $51.5M | $51.3M | $51.2M | $50.0M |
| Total assets | $508.1M | $534.0M | $404.7M | $309.3M | $337.0M |
| Total liabilities | $142.2M | $131.8M | $124.0M | $112.3M | $69.9M |
| Shareholders' equity | $365.9M | $402.2M | $280.8M | $197.1M | $267.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology